Physician profile
Catherine A Pavone
NPI 1437529385
$1,331.04
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $481 · 2023: $164 · 2024: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.31 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $348.43 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $321.45 | 2021-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $124.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $100.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.36 | 2021-2022 | |
| Exact Sciences Corporation | $77.59 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $58.59 | 2021-2022 | |
| Pfizer INC. | $40.81 | 2021-2024 | |
| Abbvie INC. | $35.19 | 2022 | |
| Tris Pharma INC | $31.73 | 2021 | |
| Astellas Pharma US INC | $23.63 | 2024 | Veozah |
| Abbott Laboratories | $22.60 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.84 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.09 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.42 | 2022 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Pavone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.